What are the indications and contraindications for ERCP in a patient with a common bile duct (CBD) stone?

ERCP Indications and Contraindications for CBD Stones

ERCP should be reserved as a therapeutic procedure only for patients with proven CBD stones, with diagnosis confirmed by non-invasive modalities (ultrasound, EUS, or MRCP) to avoid unnecessary procedural risks, particularly post-ERCP pancreatitis. 1

Indications for ERCP in CBD Stones

Strong Indications (Proceed Directly to ERCP)

• Acute cholangitis - requires urgent biliary decompression 2
• Obstructive jaundice with confirmed CBD stones 2, 3
• Gallstone pancreatitis with cholangitis or persistent biliary obstruction 4
• CBD diameter >8 mm with high suspicion of stones 2

Intermediate Risk (Consider EUS Confirmation First)

The 2017 BSG guidelines emphasize that ERCP carries inherent risks (2-5% post-ERCP pancreatitis rate) and should not be performed diagnostically 1. For intermediate-risk patients, consider:

• Elevated liver enzymes (particularly direct bilirubin and alkaline phosphatase) 3, 5
• Dilated CBD on ultrasound (≥8 mm) 5
• History of jaundice or pancreatitis 6

Critical caveat: Recent data shows that 46.4% of ESGE high-risk patients had spontaneous stone clearance when evaluated by EUS, meaning nearly half would undergo unnecessary ERCP if performed without confirmation 7. This underscores the importance of EUS verification in non-emergent cases.

NOT Indicated

• Mild gallstone pancreatitis without cholangitis - ERCP not indicated 8
• Suspected stones without objective evidence - diagnostic ERCP should be avoided 1
• "Other" vague indications - universally negative yield 9

Contraindications and Risk Mitigation

Relative Contraindications

• Coagulopathy - FBC and INR/PT must be checked prior to sphincterotomy 1
• Severe cardiopulmonary disease requiring general anesthesia considerations 1
• Inability to tolerate sedation - consider alternative approaches 1

Mandatory Risk Reduction Measures

When ERCP is performed, the following are essential to reduce morbidity:

1. Rectal NSAIDs (100 mg indomethacin or diclofenac) - administer to all patients unless contraindicated to prevent post-ERCP pancreatitis 1

2. Avoid pancreatic duct cannulation - if repeated pancreatic duct cannulation occurs (>1 wire passage), consider 5F pancreatic stent placement 1

3. Prophylactic antibiotics - NOT routinely needed unless specific risk factors present:

   • Sclerosing cholangitis
   • Communicating pancreatic cysts
   • Hilar strictures
   • Liver transplantation
   • Cholangioscopy
   • Failed biliary drainage attempt 1

4. Enhanced sedation/propofol - strongly consider for complex cases (intrahepatic stones, cholangioscopy-assisted lithotripsy) as lack of adequate sedation correlates with therapeutic failure 1

Clinical Algorithm

For suspected CBD stones:

1. Confirm diagnosis with USS, EUS, or MRCP first (avoid diagnostic ERCP)
2. If acute cholangitis or obstructive jaundice → proceed directly to therapeutic ERCP
3. If intermediate risk → obtain EUS confirmation (prevents unnecessary ERCP in ~50% of cases)
4. Administer rectal NSAIDs immediately before procedure
5. Success rate for endoscopic sphincterotomy and stone extraction: 90% 2
6. For large stones (>10-15 mm), anticipate need for lithotripsy (79% success rate, may require multiple sessions) 2

Important Pitfalls

• Post-ERCP stone remigration: 23% of patients develop recurrent CBD stones within 3 months after successful ERCP, particularly if ERCP-to-cholecystectomy interval is short 5
• Failed stone extraction: If incomplete extraction occurs, internal plastic stent placement is mandatory to ensure drainage 2
• Elderly patients: Major complication rates increase to 19% with 7.9% mortality in elderly populations 2
• Failed pancreatic stent placement: Dramatically increases post-ERCP pancreatitis risk - only attempt if properly trained 1